Mannkind (MNKD) Amortization of Deferred Charges (2020 - 2026)
Mannkind's (MNKD) quarterly Amortization of Deferred Charges came in at $532000.0 in Q1 2026, down 2.21% year-on-year from $544000.0 in Q1 2025, and up 155.36% on a QoQ basis from -$961000.0 in Q4 2025.
Mannkind (MNKD) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
Mannkind (MNKD) has 7 years of Amortization of Deferred Charges data on file, last reported at $532000.0 in Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges fell 2.21% year-over-year to $532000.0 in Q1 2026; TTM through Mar 2026 was -$266000.0, a 114.98% decrease from a year earlier, with the FY2025 full-year figure at $854000.0, down 48.12% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $532000.0, up from -$961000.0 in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for MNKD reached as high as $1.0 million in Q4 2022 and fell as low as -$961000.0 in Q4 2025.
- Historically, Amortization of Deferred Charges has averaged $365823.5 across 5 years, with a median of $363000.0 in 2022.
- Across the five-year window, Amortization of Deferred Charges surged 322.7% in 2022 and plunged 289.92% in 2025, its largest moves.
- Year by year, Amortization of Deferred Charges stood at $1.0 million in 2022, then dropped by 0.8% to $995000.0 in 2023, then sank by 49.15% to $506000.0 in 2024, then plunged by 289.92% to -$961000.0 in 2025, then surged by 155.36% to $532000.0 in 2026.
- Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $532000.0 in Q1 2026, -$961000.0 in Q4 2025, and $106000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Mannkind | 1.20 Bn | 1.07 Bn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 532,000.00 |
| Mar 31, 2026 | 532,000.00 |
| Dec 31, 2025 | -961,000.00 |
| Dec 31, 2025 | -961,000.00 |
| Sep 30, 2025 | 106,000.00 |
| Sep 30, 2025 | 106,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Mar 31, 2025 | 544,000.00 |
| Mar 31, 2025 | 544,000.00 |
| Dec 31, 2024 | 506,000.00 |
| Dec 31, 2024 | 506,000.00 |
| Sep 30, 2024 | 363,000.00 |
| Sep 30, 2024 | 363,000.00 |
| Jun 30, 2024 | 363,000.00 |
| Jun 30, 2024 | 363,000.00 |
| Mar 31, 2024 | 501,000.00 |
| Mar 31, 2024 | 501,000.00 |
| Dec 31, 2023 | 995,000.00 |
| Dec 31, 2023 | 995,000.00 |